Peripheral medulloepithelioma: A rare tumor with a potential target therapy

6Citations
Citations of this article
16Readers
Mendeley users who have this article in their library.

Abstract

Background: Medulloepithelioma (ME) is a rare embryonal tumor predominantly located in the eye or in the central nervous system without an established treatment.Case presentation: We report of a case of a localized peripheral ME treated with conventional and high dose chemotherapy, surgery and local radiotherapy. At relapse, the tumor tissue revealed a different molecular signature compared to the initial tumor mass. This molecular signature revealed a high expression of platelet derived growth factor receptor (PDGFR). Sorafenib plus irinotecan and temozolomide was started with a 5 month progression free survival.Conclusion: Our experience suggests a possible role of sorafenib or different PDGFR inhibitors in ME. Targeting treatment could represent an adjuvant and/or alternative therapy for ME and other rare tumors. © 2014 De Pasquale et al.; licensee BioMed Central Ltd.

Cite

CITATION STYLE

APA

De Pasquale, M. D., De Ioris, M. A., Gallo, A., Mastronuzzi, A., Crocoli, A., Cozza, R., & Boldrini, R. (2014). Peripheral medulloepithelioma: A rare tumor with a potential target therapy. Journal of Translational Medicine, 12(1). https://doi.org/10.1186/1479-5876-12-49

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free